血友病A治療市場- 世界の産業規模、シェア、動向、機会、予測、治療タイプ別、投与経路別、流通チャネル別、地域別、競合市場別、2020-2030F

血友病A治療の世界市場規模は、2024年に95億1,000万米ドルとなり、2030年には約136億8,000万米ドルに達すると予測され、予測期間中の年間平均成長率（CAGR）は6.22%で推移すると予測されています。

同市場は、血液凝固第VIII因子の欠乏に起因する稀な遺伝性疾患である血友病Aと診断された患者特有のニーズに対応する、より広範な医薬品・ヘルスケア市場の重要な一角を形成しています。

同市場は、血友病Aに関連する生命を脅かす可能性のある合併症の予防と管理を目的とした包括的な治療ソリューションを包含しています。主要な成長促進要因のひとつは、同疾患の世界の有病率の上昇と診断能力の向上です。遺伝学的・分子生物学的診断における認知度の向上と改善により、より多くの患者が正確に診断されるようになり、高度な治療オプションに対する需要が高まっています。

従来の治療法では、血漿または遺伝子組換え型血液凝固第VIII因子の静脈内投与が主流でした。しかし、遺伝子治療や非因子補充療法を筆頭とする次世代治療が重視されるようになり、市場は大きな転換期を迎えています。特に遺伝子治療は、疾患の根本的な遺伝的原因をターゲットにすることで、長期的あるいは治癒的な結果をもたらす可能性を提供し、変革の可能性を秘めています。

市場促進要因

有病率の上昇と診断の改善

主な市場課題

治療費の高騰

主要市場動向

遺伝子治療の出現

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界の血友病A治療市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 治療の種類別（因子補充療法、非因子補充療法、遺伝子治療）
  • 投与経路（静脈内、経口、経鼻）
  • 流通チャネル別（病院薬局、小売薬局、オンライン薬局）
  • 地域別
  • 企業別（2024）
• 市場マップ
  • 治療の種類別
  • 投与経路別
  • 流通チャネル別
  • 地域別

第5章 アジア太平洋地域の血友病A治療市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 治療の種類別
  • 投与経路別
  • 流通チャネル別
  • 国別
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第6章 欧州の血友病A治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第7章 北米の血友病A治療市場展望

• 市場規模・予測
• 市場シェア・予測
  • 治療の種類
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第8章 南米の血友病A治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第9章 中東・アフリカの血友病A治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第10章 市場力学

• 促進要因
• 課題

第11章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第12章 世界の血友病A治療市場：SWOT分析

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Takeda Pharmaceutical Company Limited
• Sanofi Corporation
• Genentech USA, Inc.
• Novo Nordisk
• Pfizer Inc.
• CSL Behring LLC.
• Grifols
• Sagent Pharmaceuticals
• Octapharma USA Inc.
• UBI Pharma Inc

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Hemophilia A Treatment Market was valued at USD 9.51 billion in 2024 and is projected to reach approximately USD 13.68 billion by 2030, growing at a compound annual growth rate (CAGR) of 6.22% during the forecast period. This market forms a vital part of the broader pharmaceutical and healthcare landscape, addressing the specific needs of individuals diagnosed with Hemophilia A-a rare genetic disorder resulting from a deficiency in clotting factor VIII.

The market encompasses a comprehensive range of therapeutic solutions aimed at preventing and managing the potentially life-threatening complications associated with Hemophilia A. One of the key growth drivers is the rising global prevalence of the disorder, coupled with increasing diagnostic capabilities. Enhanced awareness and improvements in genetic and molecular diagnostics have led to a greater number of individuals being accurately diagnosed, thereby fueling demand for advanced treatment options.

Traditional treatment modalities have predominantly relied on intravenous administration of clotting factor VIII, derived either from plasma or recombinant sources. However, the market is undergoing a significant transformation, with growing emphasis on next-generation therapies-notably gene therapy and non-factor replacement treatments. Gene therapy, in particular, holds transformative potential by targeting the root genetic cause of the disease, offering the possibility of long-term or even curative outcomes.

Key Market Drivers

Rising Prevalence and Improved Diagnosis

The growth of the Hemophilia A Treatment Market is closely linked to the increasing prevalence of the disorder and advancements in diagnostic methodologies. Hemophilia A continues to pose a considerable public health burden. According to the World Federation of Hemophilia (WFH), an estimated 179,703 individuals worldwide had been identified with Hemophilia A as of 2023. This increase is largely attributable to greater public awareness, improved diagnostic tools, and expanded genetic testing.

The WFH has outlined a five-year strategic objective (2020-2025) to increase global diagnosis by 60,000 cases, reflecting a 25% growth. Enhanced diagnostic capabilities, including molecular and genetic testing, now allow for earlier and more accurate detection of the disorder. Early diagnosis enables personalized treatment approaches, thereby improving patient outcomes and driving innovation in the development of gene-targeted therapies.

In a landmark development, the U.S. Food and Drug Administration (FDA) approved Roctavian in June 2023-the first AAV-based gene therapy for adults with severe Hemophilia A-marking a major milestone in therapeutic advancements.

Key Market Challenges

High Cost of Treatment

The high cost of treatment remains a significant barrier to widespread adoption and accessibility within the Hemophilia A Treatment Market. Managing the disorder requires lifelong therapeutic intervention, placing a substantial financial burden on both patients and healthcare systems.

One of the principal cost drivers is factor replacement therapy, which involves complex and costly manufacturing processes. Patients often require frequent infusions-sometimes multiple times per week-exacerbating the financial strain. While extended half-life products offer the benefit of reduced infusion frequency, their higher price point offsets potential savings.

Gene therapy, although promising, also introduces new cost challenges. The production of viral vectors and genetic manipulation processes involved in gene therapy are resource-intensive, resulting in exceptionally high treatment costs. These economic factors present a major constraint on broader market accessibility and adoption.

Key Market Trends

The Emergence of Gene Therapy

Gene therapy is revolutionizing the treatment paradigm for Hemophilia A. By introducing functional factor VIII genes into the patient's cells, gene therapy targets the genetic basis of the disorder and offers a potential long-term or curative solution.

This therapeutic approach eliminates or significantly reduces the need for regular factor infusions, thereby improving patients' quality of life and easing the treatment burden. Gene therapy has demonstrated promising results in clinical trials, showing the ability to sustain elevated levels of factor VIII and reduce the incidence of spontaneous bleeding episodes.

Furthermore, gene therapy addresses several of the chronic challenges associated with traditional treatments, such as inhibitor development and treatment non-compliance. Its one-time or infrequent dosing regimen enhances patient adherence and convenience, making it a game-changing development in the market.

Key Market Players

• Takeda Pharmaceutical Company Limited
• Sanofi Corporation
• Genentech USA, Inc.
• Novo Nordisk
• Pfizer Inc.
• CSL Behring LLC.
• Grifols
• Sagent Pharmaceuticals
• Octapharma USA Inc.
• UBI Pharma Inc.

Report Scope:

In this report, the Global Hemophilia A Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Hemophilia A Treatment Market, By Treatment Type:

• Factor Replacement Therapy
• Non-Factor Replacement Therapies
• Gene Therapy

Hemophilia A Treatment Market, By Route of Administration:

• Intravenous
• Oral
• Nasal

Hemophilia A Treatment Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Hemophilia A Treatment Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Hemophilia A Treatment Market.

Available Customizations:

Global Hemophilia A Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Hemophilia A Treatment Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Treatment Type (Factor Replacement Therapy, Non-Factor Replacement Therapies, Gene Therapy)
  • 4.2.2. By Route of Administration (Intravenous, Oral, Nasal)
  • 4.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 4.2.4. By Region
  • 4.2.5. By Company (2024)
• 4.3. Market Map
  • 4.3.1. By Treatment Type
  • 4.3.2. By Route of Administration
  • 4.3.3. By Distribution Channel
  • 4.3.4. By Region

5. Asia Pacific Hemophilia A Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment Type
  • 5.2.2. By Route of Administration
  • 5.2.3. By Distribution Channel
  • 5.2.4. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Hemophilia A Treatment Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Treatment Type
      • 5.3.1.2.2. By Route of Administration
      • 5.3.1.2.3. By Distribution Channel
  • 5.3.2. India Hemophilia A Treatment Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Treatment Type
      • 5.3.2.2.2. By Route of Administration
      • 5.3.2.2.3. By Distribution Channel
  • 5.3.3. Australia Hemophilia A Treatment Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Treatment Type
      • 5.3.3.2.2. By Route of Administration
      • 5.3.3.2.3. By Distribution Channel
  • 5.3.4. Japan Hemophilia A Treatment Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Treatment Type
      • 5.3.4.2.2. By Route of Administration
      • 5.3.4.2.3. By Distribution Channel
  • 5.3.5. South Korea Hemophilia A Treatment Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Treatment Type
      • 5.3.5.2.2. By Route of Administration
      • 5.3.5.2.3. By Distribution Channel

6. Europe Hemophilia A Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment Type
  • 6.2.2. By Route of Administration
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Hemophilia A Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment Type
      • 6.3.1.2.2. By Route of Administration
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Germany Hemophilia A Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment Type
      • 6.3.2.2.2. By Route of Administration
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Spain Hemophilia A Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment Type
      • 6.3.3.2.2. By Route of Administration
      • 6.3.3.2.3. By Distribution Channel
  • 6.3.4. Italy Hemophilia A Treatment Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Treatment Type
      • 6.3.4.2.2. By Route of Administration
      • 6.3.4.2.3. By Distribution Channel
  • 6.3.5. United Kingdom Hemophilia A Treatment Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Treatment Type
      • 6.3.5.2.2. By Route of Administration
      • 6.3.5.2.3. By Distribution Channel

7. North America Hemophilia A Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Type
  • 7.2.2. Treatment Type
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Hemophilia A Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment Type
      • 7.3.1.2.2. By Route of Administration
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. Mexico Hemophilia A Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment Type
      • 7.3.2.2.2. By Route of Administration
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. Canada Hemophilia A Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment Type
      • 7.3.3.2.2. By Route of Administration
      • 7.3.3.2.3. By Distribution Channel

8. South America Hemophilia A Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment Type
  • 8.2.2. By Route of Administration
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Hemophilia A Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment Type
      • 8.3.1.2.2. By Route of Administration
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. Argentina Hemophilia A Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment Type
      • 8.3.2.2.2. By Route of Administration
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Colombia Hemophilia A Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment Type
      • 8.3.3.2.2. By Route of Administration
      • 8.3.3.2.3. By Distribution Channel

9. Middle East and Africa Hemophilia A Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment Type
  • 9.2.2. By Route of Administration
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Hemophilia A Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment Type
      • 9.3.1.2.2. By Route of Administration
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Saudi Arabia Hemophilia A Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment Type
      • 9.3.2.2.2. By Route of Administration
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. UAE Hemophilia A Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment Type
      • 9.3.3.2.2. By Route of Administration
      • 9.3.3.2.3. By Distribution Channel

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Hemophilia A Treatment Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Takeda Pharmaceutical Company Limited
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Current Capacity Analysis
  • 14.1.5. Financials (In case of listed)
  • 14.1.6. Recent Developments
  • 14.1.7. SWOT Analysis
• 14.2. Sanofi Corporation
• 14.3. Genentech USA, Inc.
• 14.4. Novo Nordisk
• 14.5. Pfizer Inc.
• 14.6. CSL Behring LLC.
• 14.7. Grifols
• 14.8. Sagent Pharmaceuticals
• 14.9. Octapharma USA Inc.
• 14.10. UBI Pharma Inc

15. Strategic Recommendations

16. About Us & Disclaimer